Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

Journal of Clinical Pharmacology

Volumn 45, Issue 10, 2005, Pages 1145-1152

  Hebert, Mary F ^a   Smith, Helen E ^a   Marbury, Thomas C ^b   Swan, Suzanne K ^c   Smith, William B ^d   Townsend, Robert W ^e,f   Buell, Donald ^e   Keirns, James ^e   Bekersky, Ihor ^e,g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d New Orleans Center for Clinical Research   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^f Kos Pharmaceuticals Inc   (United States)

^g Quark Biotech Inc   (United States)

Author keywords

Liver disease; Micafungin; Pharmacokinetics; Renal disease

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; AMANTADINE; AMILORIDE; AMLODIPINE; ATORVASTATIN; CANDESARTAN; CARBAMAZEPINE; CATECHOL METHYLTRANSFERASE; CITALOPRAM; CITRATE SODIUM; COLCHICINE; DICLOFENAC; FELODIPINE; FOLIC ACID; FOSINOPRIL; FUROSEMIDE; GLIBENCLAMIDE; GLIPIZIDE; HYDROCODONE; HYDROXYZINE; IBUPROFEN; INSULIN; LORAZEPAM; MEVINOLIN; MICAFUNGIN; RANITIDINE; SPIRONOLACTONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ADULT; AGED; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA PROTEIN BINDING; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LIPOPROTEINS; LIVER DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 25444513384     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005279580     Document Type: Article

References (23)

1. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williiams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
2. Cockcroft D, Gault MK. Prediction of clearance from serum creatinine. Nephron. 1976;16:31-41.
3. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979;68:1071-1074.
4. Dufour J-F, Zimmermann A, Reichen J. Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages. J Hepatol. 1994;20:524-530.
5. Ugazio G, Artizzu M, Pani P, Dianzani MU. The changes in some hydrolytic enzymes in carbon tetrachloride-induced fatty livers. Biochem J. 1964;90:109-116.
6. Alvarez-Leal M, Contreras-Hernandez D, Chavez A, et al. Leukocyte arylsulfatase A activity in patient with alcohol-related cirrhosis. Am J Human Biol. 2001;13:297-300.
7. Bonifati V, Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther. 1999;81:1-36.
8. Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol O-methyltransferase. Nature. 1994;368:354-358.
9. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27: 135-206.
10. Reilly DK, Rivera-Calimlim L, Van Dyke D. Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther. 1980;28:278-286.
11. Campbell NRC, Dunnette JH, Mwaluko G, Van Loon J, Weinshilboum RM. Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism in man. Clin Pharmacol Ther. 1984;35:55-63.
12. Tenhunen J, Salminen M, Lundfrom K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organization of the human catechol-O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem. 1994;223:1049-1059.
13. Weinshilboum RM. Human erythrocyte catechol-O-methyltransferase: correlation with lung and kidney activity. Life Sci. 1978;22: 625-630.
14. Sladek-Chelgren S, Weinshilboum RM. Catechol-O-methyltransferase biochemical genetics: human lymphocyte enzyme. Biochem Genet. 1981;19:1037-1053.
15. Boudikova B, Szumlanski C, Maidak B, Weinshilboum R. Human liver catechol O-methyltransferase pharmacogenetics. Clin Pharmacol Ther. 1990;48:381-389.
16. Agarwal DP, Philippu G, Milech U, Ziemsen B, Schrappe O, Goedde HW. Platelet monoamine oxidase and erythrocyte catechol-O-methyltransferase activity in alcoholism and controlled abstinence. Drug Alcohol Depend. 1983;12:85-91.
17. Lachman HM, Papolos DF, Saito T, Yu Y-M, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250.
18. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Hum Genet. 1977;29:216-218.
19. Tenhunen J, Salminen M, Lundrom K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organization of the human catechol-O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem. 1994;223:1049-1059.
20. Munroe DG, Chang PL. Tissue-specific expression of human arylsulfatase-C isozymes and steroid sulfatase. Am J Hum Genet. 1987; 40:102-114.
21. Sakakibara N, Gasa S, Kamio K, Makita A, Koyanagi T. Association of elevated sulfatides and sulfotransferase activities in human renal cell carcinoma. Cancer Res. 1989;49:335-339.
22. Pazmino PA, Weinshilboum RM. Methyl conjugation in uraemic: catechol-O-methyltransferase. Br J Clin Pharmacol. 1980;10:509-518.
23. Pazmino PA, Sladek SL, Weinshilboum RM. Thiol-s-methylation in uremia: erythrocyte activities and plasma inhibitors. Clin Pharmacol Ther. 1980;28:356-367.